Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi, Shire Enter into License Agreement for Codevelopment of ADHD Treatments
November 21, 2011
- Nihon Chouzai to Introduce Electronic Drug Notebooks at All Stores
November 21, 2011
- US FDA Approves VEGF Trap-Eye for Wet AMD: Bayer Healthcare
November 21, 2011
- GSK, Daiichi Sankyo Launch Rotarix for Prevention of Rotavirus Gastroenteritis in Children
November 21, 2011
- CMIC to Establish Holding Company “CMIC HD”
November 18, 2011
- “Steady Sales in 1st Half as Result of Strict Price Lock System Operation”: President Hamada of Toho HD
November 18, 2011
- Bayer to Expand Asian Business, Focus on Chinese Market
November 18, 2011
- Teva to Merge Taiyo, Kowa-Teva, Establish “Teva Pharma Japan” in Mid-2012
November 18, 2011
- Intellim Corp. to Strengthen Contract Research System in Field of Oncology
November 18, 2011
- BMKK Applies for Add’l Indications for Taxol Based on Data in Public Domain
November 18, 2011
- Kyowa Pharm. to Buy I’rom Pharm. to Boost Sales to DPC Hospitals
November 18, 2011
- Nippon Shinyaku Grants Marketing Rights for Gaslon N･OD Tablets to Taejoon in ROK
November 18, 2011
- Meiji Seika Pharma Applies for Add’l Indications for Viccilin Based on Data in Public Domain
November 18, 2011
- Eli Lilly Japan to Provide Alimta for Free for IIT
November 18, 2011
- Fujifilm, Kyowa Kirin to Set Up Joint Venture for Biosimilars in 2012
November 17, 2011
- Takeda Initiates PII Trials of Inactivated Poliovirus, Combined 4-valent Vaccine TAD-361S in Japan
November 17, 2011
- Synix to Establish Oncology Market Research Division in December
November 17, 2011
- Zeria Aims at 50% Domestic Market Share for UC Treatment Asacol in FY2011
November 17, 2011
- High Court’s Ruling in Iressa Appeal “Extremely Fair and Reasonable”: Attorney for AZ
November 16, 2011
- Survey Finds 33% Pharmacists and Pharmacy Students Know “Established Drugs”
November 16, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…